Bivalirudin as compared to unfractionated heparin among patients undergoing coronary angioplasty: A meta-analyis of randomised trials

Thrombosis and Haemostasis

Volumn 102, Issue 3, 2009, Pages 428-436

  De Luca, Giuseppe ^a   Cassetti, Ettore ^a   Verdoia, Monica ^a   Marino, Paolo ^a  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

Acute myocardial infarction; Antithrombin; Bivalirudin; Clinical trials; Coronary angioplasty; Direct antithrombin agents

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PROTAMINE; TIROFIBAN;

BARE METAL STENT; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG SAFETY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; REVIEW; STABLE ANGINA PECTORIS; SYSTEMATIC REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

AGED; ANGIOPLASTY; ANTICOAGULANTS; HEPARIN; HIRUDINS; HUMANS; MIDDLE AGED; MYOCARDIAL REPERFUSION; PEPTIDE FRAGMENTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; STENTS; TREATMENT OUTCOME;

EID: 70449381361     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-05-0287     Document Type: Review

References (39)

1. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007; 370: 937-948. (Pubitemid 47393576)
2. De Luca G, Suryapranata H, Stone GW, et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: A meta-regression analysis of randomized trials. Int J Cardiol 2008; 126: 37-44.
3. De Luca G, Dudek D, Sardella G, et al. Adjunctive manual thrombectomy improves myocardial perfusion and mortality in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized trials. Eur Heart J 2008; 28: 3002-3010.
4. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005; 293: 1759-1765. (Pubitemid 40491302)
5. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007; 50: 1742-1751. (Pubitemid 47600591)
6. De Luca G, Marino P. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials. Am Heart J 2007; 154: 1085.e1-1086.e1. (Pubitemid 350116052)
7. Stone GW, Witzenbichler B, Guagliumi G, et al. HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-2230.
8. Chong BH, Isaacs A. Heparin-induced thrombocytopenia: what clinicians need to know. Thromb Haemost 2009; 101: 279-283.
9. De Luca G, Marino P. Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment elevation myocardial infarction. Thromb Haemost 2008; 100: 184-195.
10. Eikelboom J, White H, Yusuf S. The evolving role of direct thrombin inhibitors in acute coronary syndromes. J Am Coll Cardiol. 2003; 41 (4 Suppl S): 70S-78S. (Pubitemid 36223350)
11. Verstraete M. Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance. Thromb Haemost 1997; 78: 357-363. (Pubitemid 27289267)
12. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99: 830-839.
13. Heras M, Chesebro JH, Penny WS, et al. Effects of thrombin inhibition on development of acute platelet-thrombus deposition during angioplasty in pigs. Circulation 1989; 79; 657-665.
14. Badimon L, Badimon J, Lassila R, et al. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: effects of hirudins, heparin, and calcium chelation. Blood 1991; 78: 423-434.
15. Busch G, Steppich B, Sibbing D, et al. Bivalirudin reduces platelet and monocyte activation after elective percutaneous coronary intervention. Thromb Haemost 2009; 101: 340-344.
16. Bittl JA, Chaitman BR, Feit F, et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142: 952-959. (Pubitemid 33131801)
17. Lincoff AM, Kleiman NS, Kottke-Marchant K, et al. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am Heart J 2002; 143: 847-853. (Pubitemid 34595343)
18. Lincoff AM, Bittl JA, Kleiman NS, et al. REPLACE- 1 Investigators. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 2004; 93: 1092-1096.
19. Lincoff AM, Bittl JA, Harrington RA, et al. REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853-863.
20. Stone GW, White HD, Ohman EM, et al. Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007; 369: 907-919.
21. Kastrati A, Neumann FJ, Mehilli J, et al. ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359: 688-696.
22. Sibbing D, Busch G, Braun S, et al. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. Eur Heart J 2008; 29: 1504-1509. (Pubitemid 351881984)
23. Briguori C. Randomised Comparison of Bivalirudin Monotherapy versus Unfractionated Heparin plus Tirofiban in Diabetic Patients Undergoing Elective Coronary Stenting (NAPLES Study). http://www.clinicaltrialresults.org/ (accessed on October 16, 2008).
24. Antoniucci D. A Randomized Trial Comparing Bivalirudin With Unfractionated Heparin In Patients Undergoing Elective PCI (ARNO Trial). http://www.clinicaltrialresults.org (accessed on October 16, 2008).
25. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007; 49: 1362-1368. (Pubitemid 46476844)
26. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003; 92: 930-935. (Pubitemid 37214804)
27. Rao SV, O'Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 2005; 96: 1200-1206. (Pubitemid 41505393)
28. Agema WR, Jukema JW, Zwinderman AH, et al. A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: evidence for publication bias. Am Heart J. 2002; 144: 760-768.
29. De Luca G, Suryapranata H, Stone GW, et al. Relationship between patient's risk profile and benefits in mortality from adjunctive abciximab to mechanical revascularization for ST-segment elevation myocardial infarction: a meta-regression analysis of randomized trials. J Am Coll Cardiol 2006; 47: 685-686. (Pubitemid 43170866)
30. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896-1900.
31. Jani SM, Smith DE, Share D, et al. Blood transfusion and in-hospital outcomes in anemic patients with myocardial infarction undergoing percutaneous coronary intervention. Clin Cardiol. 2007; 30 (10 Suppl 2): II49-56 (Pubitemid 47587499)
32. Kim P, Dixon S, Eisenbrey AB, et al. Impact of acute blood loss anemia and red blood cell transfusion on mortality after percutaneous coronary intervention. Clin Cardiol 2007; 30 (10 Suppl 2): II35-43. (Pubitemid 47587497)
33. Yatskar L, Selzer F, Feit F, et al. Access site hematoma requiring blood transfusion predicts mortality in patients undergoing percutaneous coronary intervention: data from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter Cardiovasc Interv 2007; 69: 961-966.
34. Wang TY, Xiao L, Alexander KP, et al. Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation 2008; 118: 2139-2145.
35. Chase AJ, Fretz EB, Warburton WP, et al. Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg). Heart 2008 ; 94: 1019-1025.
36. Brasselet C, Tassan S, Nazeyrollas P, et al. Randomised comparison of femoral versus radial approach for percutaneous coronary intervention using abciximab in acute myocardial infarction: results of the FARMI trial. Heart 2007; 93: 1556-1561. Epub 2007 Jul 16. (Pubitemid 350205549)
37. Cantor WJ, Mahaffey KW, Huang Z, et al. Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. Catheter Cardiovasc Interv. 2007; 69: 73-83. (Pubitemid 46052595)
38. Büchler JR, Ribeiro EE, Falcão JL, et al. A randomized trial of 5 versus 7 French guiding catheters for transfemoral percutaneous coronary stent implantation. J Interv Cardiol. 2008; 21: 50-55.
39. Ducas J, Chan MC, Miller A, et al. Immediate protamine administration and sheath removal following percutaneous coronary intervention: a prospective study of 429 patients. Catheter Cardiovasc Interv 2002; 56: 196-199. (Pubitemid 34568817)